Romet (repirinast) / Bayer, Mitsubishi Tanabe, Algernon Pharma - LARVOL DELTA

Resistome and microbiome shifts in catfish rearing water: the influence of temperature and antibiotic treatments. (PubMed, Water Res) - "This study investigated the effects of three FDA-approved antibiotics (Aquaflor®, Romet®, Terramycin®) at common fish bacterial disease outbreak temperatures (20 °C, 25 °C, and 30 °C) on the microbiome and resistome of aquaculture water using a catfish model system...Of the three antibiotics tested, Terramycin exerted the most significant influence on the water microbiome and resistome, enriching tetracycline resistance genes and co-selecting for floR, sul, and dfrA genes...This is further supported by the observed reduction in plasmid numbers following treatment, which coincided with increased HGT events. Our findings highlight the pivotal role of temperature in influencing resistome dynamics, emphasizing the importance of accounting for environmental factors when applying antibiotics to effectively mitigate antimicrobial resistance in aquaculture systems."

Journal • Gene Therapies • Infectious Disease

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease (GlobeNewswire) - "Algernon Pharmaceuticals...is pleased to announce that it has received a notice of allowance from the European Patent Office (EPO) for patent application 19827430.0 for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast). The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection."

Patent • Chronic Kidney Disease • Fibrosis

Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent (GlobeNewswire) - "Algernon Pharmaceuticals Inc...is pleased to announce that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/255,364 for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast). The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection."

Patent • Chronic Kidney Disease

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD (BioSpace) - "Algernon Pharmaceuticals Inc...announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled 'Compositions and Methods for Treating Non-Alcoholic Steatohepatitis' with NP-251 (Repirinast). The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast."

Patent • Metabolic Disorders • Non-alcoholic Steatohepatitis

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH (GlobeNewswire) - "Algernon Pharmaceuticals Inc...is pleased to announce that it has been issued a patent from the United States Patent and Trademark Office (USPTO), No. 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast)....The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast. The base claims of the patent will be valid through 2039, excluding any patent term adjustments or extensions which may provide additional protection. The Company has also filed corresponding patent applications in Canada, Europe, China and Japan."

Patent • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

Algernon Pharmaceuticals receives Notice of Allowance from Japanese Patent Office for Repirinast (Proactiveinvestors) - "Algernon Pharmaceuticals...received a Notice of Allowance from the Japanese Patent Office (JPO) for a patent application for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast). The company said it has also filed corresponding patent applications in the US, Canada, Europe and China."

Patent • Chronic Kidney Disease • Idiopathic Pulmonary Fibrosis • Renal Disease

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application (GlobeNewswire) - "Algernon Pharmaceuticals Inc...is pleased to announce that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/258,402 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast). The Company has also filed corresponding patent applications in Canada, Europe, China and Japan. The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast. The company previously disclosed that Repirinast, in a widely used STAM™ mouse model of NASH from SMC Laboratories (Japan)."

Patent • Non-alcoholic Steatohepatitis

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study (GlobeNewswire) - "Algernon Pharmaceuticals Inc...is pleased to announce that its lead chronic kidney disease ('CKD') drug NP-251 ('Repirinast'), reduced fibrosis by 56% with statistical significance, in a preclinical study investigating non-alcoholic steatohepatitis ('NASH') in the STAM™ mouse model from SMC Laboratories (Japan). Repirinast was one of multiple drugs that Algernon screened in a NASH preclinical animal study where liver tissue samples from the Repirinast treatment group underwent a pathology review using sirius red staining. The tissue analysis showed that when compared to the negative control group, Repirinast (60mg/kg QD) reduced fibrosis by 56% (p<0.0001). In the same study, Ifenprodil (4 mg/kg, TID) showed a 56% reduction in fibrosis vs. untreated controls (p=0.015)."

Preclinical • Idiopathic Pulmonary Fibrosis

Comparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam (clinicaltrials.gov) - P4; N=90; Not yet recruiting; Sponsor: TC Erciyes University

New P4 trial • Biosimilar • Pain

A Phase 2 Study of Fosbretabulin in Subjects With Gastrointestinal Neuroendocrine Tumors (GI-NET) and With Elevated Biomarkers (clinicaltrials.gov) - P2; N=20; Not yet recruiting; Sponsor: OXiGENE

New P2 trial • Biosimilar • Oncology

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=17; Active, not recruiting; Sponsor: National Cancer Institute (NCI); N=40 -> 17

Enrollment change • Biosimilar • Immunology • Oncology